Articles15th, 2009.
Clinical Efficacy of Systemic Enzyme Support, by Joseph J Collins, RN, ND
Clinical
observations and literature review both affirm the conviction that
systemic enzyme support
with Wobenzym® N or Wobenzym® PS
is an essential component for successful management of inflammation
disorders and other conditions with immune system dysregulation due
to its high degree of clinical efficacy. In addition to improving
clinical outcomes in conditions with overt inflammation, such as
rheumatoid arthritis, thrombophlebitis, pyelonephritis, prostatitis
and psoriasis, systemic enzyme support is also affective in
conditions with covert inflammation such as osteoarthritis, angina,
atherosclerosis, myocardial infarctions, and diabetes to name a few.
The adjuvant properties of systemic enzyme support have also been
observed and documented for a number of cases including adnexitis,
arthritis, papillomas and various forms of cancer. This article will
familiarize clinicians with the therapeutic benefits of systemic
enzyme support and review pertinent findings related to this
treatment modality.
Enzymes are biological molecules that increase the rate of chemical
reactions. In the human body, thousands of chemical reactions occur
during the course of normal metabolic processes. These reactions
require significant energy in order to take place. Enzymes act as
catalyst to lower the energy needed for the reaction to move
forward. As such, enzymes maintain optimal function of the various
systems in the body and support overall good health and optimal
quality of life.
The immune system is very dependent on proper
enzyme function in regards to regulating inflammation as well as
protecting cells from damage. Cytokine activity, and the clearance
of excessive inflammatory cytokines, is regulated by proteases,
enzymes which degrade proteins. The clearance of tissue proteins and
peptides damaged by inflammation is also mediated by proteases.
Proteases significantly reduce concentrations of advance glycation
end-products (AGEs) and protect cells by decreasing their receptor
(RAGEs) activation. Proteases also down-regulate adhesion molecule
activity in inflamed, as well as malignant cells.
Inflammation
Observed
This
inflammation response can be quite aggressive, and manifest as the
five cardinal signs of inflammation recognized ages ago: redness,
heat, swelling, pain and loss of function, classically referred to
in Latin as rubor, calor, tumor, dolor & functio laesa. Pain, loss of function,
and other cardinal signs of inflammation diminish our quality of
life and may be a harbinger of serious disease. Therefore,
clinically evident inflammation is often recognized as the body
communicating an inability to control proper cellular processes.
In addition to the clinical signs of inflammation, laboratory tests
often show increased levels in the various biomarkers of
inflammation that are also associated with increased morbidity and
mortality. These include the well known
erythrocyte sedimentation rate (ESR) and C-Reactive Protein (CRP).
Circulating Immune Complexes (CICs), and immunoglobulins (IgG, IgE,
IgA & IgM) are often elevated by excessive inflammation. Excessive
fibrin activity and increased amyloid beta-peptide can also be
quantified in the presence of imbalanced inflammation. Certain
cytokine levels may also increase, which may cause further imbalance
in the immune system.
The change in certain cytokine levels is of specific interest
because it allows us to recognize when the immune system has become
significantly imbalanced, and provides us with insight into how
immunomodulation can be achieved through the use of systemic
enzymes.
Inflammation & Cytokines
Cytokines are signaling proteins and glycoproteins involved in
cellular communications that play a dominant role in maintaining the
normal inflammatory processes of the immune system. Cytokines such
as interferon-gamma (INF-γ),
tumor necrosis factor-alpha (TNF-α),
transforming growth factor beta (TGF-β)
and interleukins (IL-2, IL-6, IL-12, IL-4, IL-5, IL-10) are produced
de novo (on demand) in various cells as a direct response to
stimulation of the immune system. They are produced by a wide
variety of cells
Since excessive cytokines are involved in auto-aggressive
inflammatory processes, the binding to cytokines and the removal of
cytokines by the activated α-2- macroglobulin proteins support a
balanced and properly functioning immune system. Therefore
the removal of excessive cytokines allows the immune system to
restore Th1/Th2 balance. Once cytokine levels are restored to their
optimal physiologically balanced state the immune system is able to
resume its function of protecting the body and initiating the
healing process.
With renewal of the normal inflammatory process the regenerative
processes of the immune system are again allowed to function.
As noted, the clearance of excessive
cytokines, the clearance of
proteins and peptides damaged by inflammation, the inactivation of
advance glycation end-products, and the inactivation of adhesion
molecules in inflamed and malignant cells are all mediated by
proteolytic enzymes. A balanced immune system – immunostasis – can
be manifested by using systemic enzyme support, which provides the
essential proteolytic enzymes. Systemic enzyme support can be
defined as a treatment modality which uses oral administration of
exogenous hydrolytic (mainly proteolytic) enzymes of animal origin (trypsin,
chymotrypsin) and plant origin (bromelain, papain) in the form of
enteric-coated tablets for supporting healthy and normal
inflammatory processes in the body.
Systemic enzyme support (SES) which uses
Wobenzym® N and Wobenzym® PS -
clinically validated formulations of enzymes from both plants and
animals - is able to influence immunity in such a fashion as to
reduce pain, swelling, inflammation, edema and lymphedema, and
increase fibrinolysis, and the clearance of harmful immune complexes
that are a result of antibody reactions. SES provides enzymes which
can be utilized to assist the body’s various regulatory and
communications systems and supports the function of tissues at a
cellular level. SES has application for degenerative diseases,
autoimmune diseases, and as an adjuvant to improve efficacy of anti-infectives
in infectious diseases.
A significant amount of the published international literature
describing the clinical benefits of systemic enzyme support is based
on various systemic enzyme support formulations made for many
decades by MUCOS Pharma, a Germany pharmaceutical company. Even
after the sale of MUCOS Pharma, Wobenzym® N is still
manufactured in Germany, but is distributed by MUCOS, LLC, an
American company.
The history of Wobenzym® is significant in that systemic
enzyme support requires sophisticated processing techniques to be
effective.
Systemic enzyme support formulations are considered prescription
drugs in part of Europe, and manufactured to the same high standards
of pharmaceuticals.
The Wobenzym® N and Wobenzym® PS
enteric coated, animal enzyme, plant enzyme and rutosid combinations
are the most researched systemic enzyme formulations in the world;
and used by athletes, doctors and millions of people to help
normalize inflammation, speed recovery from sports and other routine
injuries, and promote healthy circulation.
The active constituents in Wobenzym® N and Wobenzym®
PS are
delivered through tablets that have a special enteric coating which
can withstand the acid environment in the stomach, which is
important since enzymes can be damaged by stomach acid. Once the
tablet has passed a safe distance from the stomach acids, the tablet
dissolves and the enzymes are efficiently absorbed by the mucosal
membrane of the intestine. This process is most effective if the
tablets are taken away from meals.
Conditions Treated with Systemic Enzyme Support
Based on clinical observations and literature review systemic enzyme
support effectively improves the treatment of conditions with an
auto-aggressive component by promoting the decomposition and
elimination of disease associated circulating immune complexes.
Improvements in CRP, ESR and other biomarkers of inflammation are
also noted. Clinical improvement is noted in a wide range of
conditions, with benefits observed in treating various body systems.
Nervous system disorders such as multiple sclerosis showed a
decreased number and duration of attacks because of decreased
inflammatory activity due to systemic enzyme support.13-15
A notable increase in the degradation and clearance of the amyloid
beta (A beta) peptide can reduce the risk of developing Alzheimer’s
disease.16-21
The cardiovascular system benefits by reduced risks of re-infarction
after an MI because of the hypolipidemic and immunonormalizing
benefits of systemic enzyme support.22-24 Patients with
stable angina pectoris had a demonstrable reduction in the frequency
and intensity of angina pectoris attacks and increased tolerance of
physical work load with systemic enzyme support.25
Disease of venous system, including acute thrombophlebitis and
postthrombophlebitic syndrome were dramatically improved by systemic
enzyme support, with a notable decrease of pain, reduction of edema
and trophic ulcers.26-29 Other research showed highly
effective resolution of lymphedema in both upper and lower
extremities due to fibrinolytic & antiedematous effects of systemic
enzyme support.33-36
Respiratory system health is improved by systemic enzyme support
with a notable reduction of both frequency and severity of recurrent
respiratory tract infections. Researchers have concluded that
systemic enzyme support represents a novel therapeutic modality
helping in the treatment of children showing a high sickness rate
and note that the as number and severity of dyspnea attacks
decreased in children with proven asthma.37,38
Integumentary conditions had improved clinical success when systemic
enzyme support was added as an adjuvant with other conventional
therapies. The inclusion of systemic enzyme support in treatment of
psoriasis significantly decreases the exudative component of
exacerbation, increased regression and decreases recurrence.39
Eczema (atopic dermatitis) treated with only systemic enzyme support
was able to reduce skin itching manifestations, and in combination
with basic conventional therapies it provided an marked acceleration
of the desirable effects.40
Urinary system condition improvement due to treatment with systemic
enzyme support include a major improvement in relapsing urinary
tract infections, decreased recurrence of kidney stones and
decreased progression of diabetic nephropathy. There are also
positive clinico-laboratory results, which considerably exceeded
those in conventional drug treatment in patients with
pyelonephritis.41-45
Reproductive health, women’s health, men’s health and thyroid health
conditions can all be more effectively managed by the use of
systemic enzyme support. It is an important part of the complex
therapy of male and female sterility, recurrent miscarriages and
chronic infections of the reproductive system. Systemic enzyme
support is an effective immunomodulator for both autoimmune &
alloimmune infertility.46-48 In women, it is effective
for treatment in chronic pelvic inflammatory disease (PID) and as
adjuvant in treatment of acute adnexitis.49-50 In men,
systemic enzyme support is a very efficient therapy for both
bacterial and abacterial prostatitis, as well as associated sexual
dysfunction.51-53 Systemic enzyme support is also a very
effective therapy for the management of fibrocystic breast disease
and does not interfere with already upset hormonal balance.54-56
Autoimmune thyroid disease treated with systemic enzyme support
resulted in a significant decrease of TSH, anti-TG & anti-TPO and
allowed the lowering of L-thyroxine dosages.57
Sports medicine is another area in which systemic enzyme support
excels. Sport & exercise related muscle pain & inflammation provoked
by a strong physical tension, excessive training and heavy
competition rate are decreased with “excellent results” due to the
selective interferences of enzymes with the pathophysiologic
mechanisms of exercise induced inflammation.73 A
prophylactic administration of systemic enzyme support in top
athletes who are at risk of injury results in significantly reduced
duration of injury symptoms and in absence from training and work
due to such injuries. Systemic enzyme support also improves recovery
from sprains, as well as shortened recovery from sport injuries
severe enough to also require surgery.74-77
Biomarkers of Inflammation & Systemic Enzyme Support
It is again important to note that the studies showing clinical
efficacy in the aforementioned conditions are based on the enteric
coated polyenzyme formulations which originated from Germany.
Clinicians can be confident that they will observe the same degree
of clinical efficacy with Wobenzym® N, and Wobenzym®
PS, which are manufactured in Germany by that company. As well as
the clinically observable benefits, systemic enzyme support improves
the levels of a number of biomarkers of inflammation as mentioned
above.
Systemic enzyme support resulted in improvement or normalization in
a number of biomarkers of inflammation. The decreased circulating
immune complex (CIC) levels resulted in significant improvement in a
wide range of conditions including rheumatoid arthritis,
atherosclerosis, atopic dermatitis, Behçet's disease, chronic
hepatitis, diabetes mellitus, and myocardial infarction.78-87.
Decreased erythrocyte sedimentation rate was observed in urinary
tract infections, adnexitis, rheumatoid arthritis, and surgical
cases.88-93 Decreased C-reactive protein (CRP) levels in
lymphedema, rheumatoid arthritis, psoriatic arthritis and surgical
cases was associated with improved clinical outcomes.94-96
The normalization of cytokine levels after tissue injury and
inflammation was observed in rheumatoid arthritis and angina
pectoris treated with systemic enzyme support.97-100
Normalization of immunoglobulins (IgG, IgE, IgA, IgM) is observable
in treated cases of atopic dermatitis, recurrent infections of
respiratory tract and rheumatoid arthritis.101-103 The
restoration of normal fibrinolytic properties by systemic enzyme
support is considered as vital for disease state management in
rheumatology, immune complex diseases, traumatology, surgery,
oncology, inflammations and vascular diseases as well as diseases
with an infection component.104,105 Systemic enzyme
support can also up-regulate amyloid beta catabolism and reduce the
risk of developing Alzheimer’s disease by preventing amyloid beta
accumulation in brain and vasculature.106-111
Clinical Conclusions
Systemic enzyme support has been demonstrated to be an effective
treatment either as the primary therapy, or as an adjuvant therapy
which improves clinical outcomes of diseases which are difficult to
manage. Systemic enzyme support has been reported to have excellent
tolerance and superior safety when compared to some conventional
therapies.112-116 The safety and efficacy of systemic
enzyme support is coupled with a consumer loyalty rate of over 80
percent. This significant compliance to systemic enzyme support is
believed to be primarily due to its effectiveness
More information can be found at
www.SystemicEnzymeSupport.org,
a non-commercial a health education and wellness promotion website
dedicated to teaching the clinical efficacy of systemic enzyme
support.
[3] - LaMarre J, Wollenberg GK, Gonias SL, Hayes MA.
Cytokine binding and clearance properties of proteinase-activated
alpha 2-macroglobulins. Lab Invest. 1991 Jul;65(1):3-14.
[4] - French K,
Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin
modulates a chaperone-like action with broad specificity.
Biochemistry. 2008 Jan 29;47(4):1176-85.
[5] - Lauer D, Reichenbach A, Birkenmeier G. Alpha
2-macroglobulin-mediated degradation of amyloid beta 1--42: a
mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001
Feb;167(2):385-92.
[6] - Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ.
Degradation of amyloid beta-protein by a serine
protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr
5;271(14):8443-51.
[7] - Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA,
Paul SM. alpha2-Macroglobulin as a beta-amyloid peptide-binding
plasma protein. J Neurochem. 1997 Jul;69(1):299-305.
[8] - Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel
NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid
peptide and prevents fibril formation. Proc Natl Acad Sci U S A.
1998 Mar 17;95(6):3275-80.
[9] - Mettenburg JM, Gonias SL. Beta-amyloid peptide binds
equivalently to binary and ternary alpha2-macroglobulin-protease
complexes. Protein J. 2005 Feb;24(2):89-93.
[10] - Qiu Z, Strickland DK, Hyman BT, Rebeck GW.
Alpha2-macroglobulin enhances the clearance of
endogenous soluble beta-amyloid peptide via low-density lipoprotein
receptor-related protein in cortical neurons. J Neurochem. 1999
Oct;73(4):1393-8.
[11] - Misra UK, Sharma T, Pizzo SV. Ligation of cell
surface-associated glucose-regulated protein 78 by
receptor-recognized forms of alpha 2-macroglobulin: activation of
p21-activated protein kinase-2-dependent signaling in murine
peritoneal macrophages. J Immunol. 2005 Aug 15;175(4):2525-33.
[12] - Feldman SR, Ney KA, Gonias SL, Pizzo SV. In vitro binding and
in vivo clearance of human alpha 2-macroglobulin after reaction with
endoproteases from four different classes. Biochem Biophys Res
Commun. 1983 Jul 29;114(2):757-62.
[13] - Mertin J.1, Stauder G., ESEMS working group. Use of oral
enzymes in multiple sclerosis patients. Inter. Journal of
Tissue Reactions 1997, Vol. XIX , No.1/2, pp 95.
[14] - Hana Krejcová. Wobenzym® and Wobe-Mugos® in the Treatment of
Multiple Sclerosis.
PharmaScript, Kathi-Kobus-Steig 1, D-82515 Wolfratshausen, Germany.
[15] - Stauder G., Donnerstag B., Baumhackl U., Buschmans E. Use of
oral enzymes in multiple sclerosis: phenotyping of peripheral blood
lymphocytes from MS patients under long-term treatment with orally
administered hydrolytic enzymes. Inter. Journal of Immunotherapy
1997, Vol. XIII, No. 3/4, pp 135-137.
[16] - Lauer D, Reichenbach A, Birkenmeier G. Alpha
2-macroglobulin-mediated degradation of amyloid beta 1--42: a
mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001
Feb;167(2):385-92.
[17] - Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ.
Degradation of amyloid beta-protein by a serine
protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr
5;271(14):8443-51.
[18] - Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA,
Paul SM. alpha2-Macroglobulin as a beta-amyloid peptide-binding
plasma protein. J Neurochem. 1997 Jul;69(1):299-305.
[19] - Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel
NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid
peptide and prevents fibril formation. Proc Natl Acad Sci U S A.
1998 Mar 17;95(6):3275-80.
[20] - Mettenburg JM, Gonias SL. Beta-amyloid peptide binds
equivalently to binary and ternary alpha2-macroglobulin-protease
complexes. Protein J. 2005 Feb;24(2):89-93.
[21] - Qiu Z, Strickland DK, Hyman BT, Rebeck GW.
Alpha2-macroglobulin enhances the clearance of
endogenous soluble beta-amyloid peptide via low-density lipoprotein
receptor-related protein in cortical neurons. J Neurochem. 1999
Oct;73(4):1393-8.
[22] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N.,
Fisenko L.I. Systemic enzyme treatment as a method of secondary
prevention in patients after myocardial infarction in the
rehabilitation period. II Mediterranean Congress of Physical
Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain.
Abstracts- pp. 137 489 KA (19-08-3).
[23] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A.,
Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U. Systemic enzyme
therapy in the treatment of patients with myocardial infarction.
Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.
[24] - Kovalenko V.N., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko
T.I., Terzov A.I. N.D. Strazhesko New approaches to modern
cardiology based on systemic enzyme therapy. Int. J. Immunotherapy
2001, Vol. XVII, No. 2/3/4, pp. 101-111.
[25] - Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F.
Systemic enzyme therapy in the complex treatment of angina pectoris.
Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120.
[26] - Kopadze, T.Sh., Natsvlishvili, G.A., Tvaladze, M.G.,
Avazashvili, D.N. Application of Wobenzym and Phlogenzym to the
angiology and vascular surgery. Georgian Medical News 2001, No. 2,
(serial No.71), pp. 27 – 29.
[27] - Koshkin V.M., Kirienko A.I., Leontjev S.G., Agafonov V.F.
Systemic enzyme therapy of lower limb postphlebitic syndrome.
Angiology and vascular surgery 2000, Vol. 6, No. 2, pp. 61 – 64.
[28] - Džupina A., Džupinová M. Wobenzym in the treatment of
Thrombophlebitis. Praktická flebologie 1998, Roè. 7, è. 1, str.
28-30 (17-12-3).
[29] - Valery M. Koshkin, M.D., D.M.Sci.Wobenzym® in the Treatment
of Acute Thrombophlebitis. PharmaScript, Kathi-Kobus-Steig 1,
D-82515 Wolfratshausen, Germany.
[30] - Wald M. Diagnosis and treatment of lymphedema. Interní
medicína pro praxi 2003, č. 8, str. 415-417.
[31] - Kafková H., Kojanová M. Lymphedema. Postgraduální medicína
2003, 5 (6), pp. 626 – 633.
[32] - Dzupina A., Morvay P., Dzupinova M. Systemic enzyme therapy
and complex decongestive therapy in the patients with primary and
secondary lymphedema of lower extremity. Lymfo 2000, Praha 13. - 14.
10. 2000. Praktická flebologie - supplement 2000, Roè. IX, str.
23-27. (17-13-2)-(17-12-1).
[33] - Dusková M, Wald M. Orally administered proteases in aesthetic
surgery. Aesthetic Plast Surg. 1999 Jan-Feb;23(1):41-4.
[34] - Dzupina A., Morvay P., Dzupina M. Proteolytic enzymes in
lymphedema therapy. 41st Annual World Congress - ICA'99,
International College of Angiology, Sapporo, Japan, July 3-10, 1999,
Scientific Posters pp. 76.
[35] - Korpan MI, Fialka V. Wobenzyme and diuretic therapy in
lymphedema after breast operation. Wien Med Wochenschr.
1996;146(4):67-72; discussion 74.
[36] - Kasseroller R., Wenning H.G. Efficacy and tolerability of
proteolytic enzymes as an anti-inflammatory agent in lymphoedema
after axillary dissection due to mammary cancer. The European
Journal of Lymphology, 2002-2003, Vol. 10, No. 37-38, pp. 18-26,
[37] - Vokálová I. Systemic enzyme therapy in the treatment of
children with recurrent infections of respiratory tract. Vox
Pediatriae 2003, Vol. 2., No. 9, pp. 29 – 30.
[38] - Shved M.I., Dubkova G.I. Therapeutic efficacy of Wobenzym in
patients with focal pneumonia. Visnik naukovych doslidženij 1999,
No. 2, pp. 79-82.
[39] - Milus I.E. Wobenzym in the treatment of patients with
psoriasis. Zurnal dermatologii i venerologii 1998, 2 (6), 35-36.
[40] - Samtsov A.V., Mazurov V. I., Tabachnov V.V. Systemic enzyme
therapy in the treatment of neurodermitis (atopic dermatitis)
patients. Skin and Venereal Diseases Department of
Sankt-Petersburg’s Military Medicine Academy Conference "New aspects
of systemic enzyme therapy", Moscow, 1999.
[41] - Schved N.I., Martyniuk L.P. Clinico-laboratory evaluation of
treatment efficacy in chronic pyelonephritis patients with Wobenzym.
Vratschebnaya praktika 1997, 4, 38-42.
[42] - Schlüter. P. Phlogenzym® in patients with relapsing urinary
tract infections: Efficacy & Tolerance. Schlüter. Gartenstraße 96,
D-69502 Hemsbach, Germany. Report by: MUCOS Pharma GmbH & Co, Abt.
Klinische Forschung, Kirchplatz 8, D-82538 Geretsried, Germany
[43] - Borisov O.V. Coenzyme metabolic assurance of patients with
recurrent nephrolithiasis in the complex treatment by systemic
enzyme therapy. Urologia 1998, 3, pp. 29-35.
[44] - Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov S.A.
Immunological aspects of systemic enzyme therapy (SET) in the
complex treatment of recurrent nephrolithiasis. 1st National
Congress of the Ukraine on Immunology, Allergology, and
Immunorehabilitation.
[45] - Stauder G., Wood G., Paczek L. Enzyme Therapy in Diabetic
Nephropathy – Experimental and First Clinical Data. 6th Taormina
Course of Nephrology. October 20th - 22th, 2000, pp. 227-232,
Editoriale Bios 2000
PZ 22 (5-14-3)-(19-11-3).
[46] - Nouza K., Madar J. Immunomodulation in the treatment of
reproduction disturbances. American Journal of Reproductive
Immunology 2001, Vol. 46, No. 1, pp. 106.
[47] - Ivaniyta L.I., Ivaniyta S.O., Kornatskaya A.G., Belis N.I.,
Kondratiyk. Systemic enzyme therapy in the treatment of chronic
salpingitis and infertility. Farm. Zh. (Kiev) 1998, No. 2, pp.
89-92.
[48] - Dittmar, F.-W. Enzyme therapy - a method of immune therapy
for immunologically caused habitual abortion. Forum Immunologie
2000, No. 3/2000, II - VIII.
[49] - Friedrich, F.
Wobenzym® in the Treatment of Chronic Pelvic Inflammatory Disease.
Study NR.: MU-89210. Germany Report provides through: PHARMASCRIPT,
Kathi Kobus increase 1, W-8190 Wolf-advice-live, to Germany Report:
30. 5. 1989.
[50] - Dittmar F.-W., Weissenbacher E. R. Therapy of adnexitis -
enhancement of the basic antibiotic therapy with hydrolytic enzymes.
International Journal of Experimental and Clinical Chemotherapy
1992: Vol. 5, No. 2, pp. 73-81.
[51] - Schlüter, P. Phlogenzym® in the Treatment of Chronic
Prostatitis. PharmaScript, Primelweg 2, D-82538 Geretsried, Germany
Date of report: October 30th, 1997.
[52] - Schlüter P. Efficacy and tolerance of oral enzyme therapy in
chronic prostatitis: Results of a double-blind therapy study.
European Journal for Infectious and Immunological Diseases 1998,
Vol. 2, pp. 57-69.
[53] - Izbasarov A.I., Ismoldaev E.S., Khusainov T.E. Special
treatment of patients suffering from a mixed copulatory dysfunction
with interoreceptive syndrome. 3rd Urology Congress of Khazakhstan
May 25-26, 2000., Almaty.
[54] - Loginova N.S., Naumkina N.G., Sukhikh G.T. Wobenzym in
therapy of various forms of fibrocystic disease with individually
selected immunomodulators. International congress "Advances in
Immunology and Allergology at the Treshold
of the XXI Century" May 3-6, 2000, Eilat, Israel.
[55] - Rammer E, Friedrich F. Enzyme therapy in treatment of
mastopathy. A randomized double-blind clinical Study.
Wien Klin Wochenschr. 1996;108(6):180-3.
[56] - F. W. Dittmarl, W.
Luh.
Treatment of fibrocystic mastopathy with
hydrolytic enzymes. International J. of Experimental and Clinical
Chemotherapie 1993: Vol. 6, No. 1, pp. 9-20 WE 13 (5-03-1) = WE 49
(5-04-1) nìm.
[57] - Kvantchakhadze R.G. Wobenzym in the complex treatment of
autoimmune thyroiditis. International Journal on
Immunorehabilitation, 2002,
Vol. 4, No. 1, pp. 114.
[58] - Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme
combination versus diclofenac in the treatment of osteoarthritis of
the knee--a double-blind prospective randomized study. Clin
Rheumatol. 2004 Oct;23(5):410-5. Epub 2004 Jul 24.
[59] - Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and
tolerance of an oral enzyme combination in painful osteoarthritis of
the hip. A double-blind, randomised study comparing oral enzymes
with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006
Jan-Feb;24(1):25-30.
[60] - Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W.
Efficacy and tolerability of oral enzyme therapy as compared to
diclofenac in active osteoarthrosis of knee joint: an open
randomized controlled clinical trial. J Assoc Physicians India. 2001
Jun;49:617-21.
[61] - Guseinov N.I. Wobenzym in therapy of rheumatoid arthritis.
International Journal on Immunorehabilitation 2001, Vol. 3, No. 2,
pp. 73-74.
[62] - Shalamberidze L., Kartvelishvili E., Astvatsaturova T. The
results of long-term use of Wobenzym in complex management of
rheumatoid arthritis. International congress "Advances in Immunology
and Allergology at the Treshold of the XXI Century" May 3-6, 2000,
Eilat, Israel.
[63] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[64] - Klein G., Kullich W. Pain Reduction in Rheumatic Diseases by
Oral Therapy with Enzymes. Wien. Med. Wschr. 1999, 149, pp. 577-580.
[65] - Szilasiová A., Macejová Ž., Jautová J., Pundová L. Our
experience with Wobenzym in the treatment of patients with
rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78,
No. 7, pp. 366-368.
[66] - Siziakina L.P., Artemenko N.A. Clinical and immunological
criteria of activity of different rheumatic arthritis courses and
their treatment by Wobenzym. III. Internat. Congress on
Immunorehabilitation and Rehabilitation in Medicine, Eilat, Israel,
1997.
[67] - Kovalenko V.M., Golovkov Y.Z. New possibilities of basic
therapy in patients with rheumatoid arthritis on the basis of
systemic enzyme therapy. Reumatologia 1998, Suppl Vol. XXXVI, Warsaw
1998, Lectures No. 212, pp 110-111.
[68] - Shaivok A.V., Movsisyan G.R., Stolyarova A.V. Wogenzym(R) in
teh Treatment of Patients with Juvenile Chronic Arthritis. INt. J.
Immunotherapy XIII(3/4) 93-96 (1997).
[69] - Kovalenko V.,Golovkov Y., Golovatcky I. Using of systemic
enzymotherapy for treatment of rheumatoid arthritis. Rheumatologia
1998, Suppl., Vol. XXXVI, Warsaw 1998, Abst. No. 140, pp. 206.
[70] - Szilasiová A., Macejová Ž., Jautová J., Pundová L. Our
experience with Wobenzym in the treatment of patients with
rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78,
No. 7, pp. 366-368.
[71] - Kovalenko V.N., Golovkov Y. Z. Basic treatment of rheumatoid
arthritis: new approaches. Revmatology in Europe 1997, Vol. 26,
Suppl. 2, Abst. 446.
[72] - Kovalenko V.N., Siniatchenko O.V., Ignatchenko G.A., Terzov
A.I., Grin V.K., Lauschkina E.M.Systemic enzyme therapy in the gout
treatment. Ukrainskii kardiologitschnyi zurnal 1998: 1, 53-56.
[73] - Nouza K. Physical activity and immune system. Systemic enzyme
therapy in prevention and treatment. Medicina Sportiva Boh. Slov.
1997, Vol. 6., No. 2, pp. 41 - 45.
[74] - Zuschlag J.-M. Prophylactic administration of Wobenzym to
reduce consequences of sports injuries in karate fighters. MUCOS
Pharma GmbH & Co, Dept. Clinical Research, Geretsried, Germany.
[75] - Kerkhoffs GM, Struijs PA, de Wit C, Rahlfs VW, Zwipp H, van
Dijk CN. A double blind, randomised, parallel group study on the
efficacy and safety of treating acute lateral ankle sprain with oral
hydrolytic enzymes. Br J Sports Med. 2004 Aug;38(4):431-5.
[76] - Nouza K. Physical activity and immune system. Systemic enzyme
therapy in prevention and treatment. Medicina Sportiva Boh. Slov.
1997, Vol. 6., No. 2, pp. 41 – 45.
[77] - Naumenko L. Yu. Use of systemic enzyme therapy in the
treatment of hand injuries and their consequences.Presented at the
conference ”Current treatment aspects of wrist injuries and their
consequences”, Dnepropetrovsk 1998
[78] - Vassilenko A.M., Fessenko V.I., Schvets S.V. Efficacy of
systemic enzyme therapy in the treatment of patients with chronic
hepatitis B. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp.
93-97.
[79] - Orekhov A.N., Kalenich O.S., Tertov V.V., Novikov I.D.
Lipoprotein Immune Complexes As Markers of
AtherosclerosisLipoprotein Immune Complexes As Markers of
Atherosclerosis. Inter. Journal of
Tissue Reactions 1991, Vol. XIII, No. 5, pp. 233-236.
[80] - Dzivite I., Sochnevs A., Stauder G., Zeibarts M., Lauga U.,4
Ansbergs J. Regular intake of Wobenzym® may prevent late
complications in diabetes mellitus. Int. J. Immunotherapy 2001, Vol.
XVII, No. 2/3/4, pp. 143-148- ISSN 0255-9625 218 K/375 (19-05-3).
[81] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N.,
Fisenko L.I. Systemic enzyme treatment as a method of secondary
prevention in patients after myocardial infarction in the
rehabilitation period. II Mediterranean Congress of Physical
Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain.
Abstracts- pp. 137 489 KA (19-08-3).
[82] - Wrba H. Systemic Enzyme Therapy - Newest Status and Progress.
Therapie Woche 1987, Jahrgang 37, No. 7
SO 11 (19-02-3).
[83] - Samtsov A.V., Mazurov V. I., Tabachnov
V.V. Systemic enzyme therapy in the treatment of neurodermitis
(atopic dermatitis) patients. Skin and Venereal Diseases Department
of Sankt-Petersburg’s Military Medicine Academy Conference "New
aspects of systemic enzyme therapy", Moscow, 1999.
[84] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A.,
Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U. Systemic enzyme
therapy in the treatment of patients with myocardial infarction.
Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.
[85] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[86] - Kartvelishvili E., Shalamberidze L., Torondjadze M. The
results of long-term use of Wobenzym in complex management of
Behcet's disease. International congress "Advances in Immunology and
Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat,
Israel.
[87] - Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov S.A.
Immunological aspects of systemic enzyme therapy (SET) in the
complex treatment of recurrent nephrolithiasis. 1st National
Congress of the Ukraine on Immunology, Allergology, and
Immunorehabilitation.
[88] - Schlüter. P. Phlogenzym® in patients with relapsing urinary
tract infections: Efficacy & Tolerance. Schlüter. Gartenstraße 96,
D-69502 Hemsbach, Germany. Report by: MUCOS Pharma GmbH & Co, Abt.
Klinische Forschung, Kirchplatz 8, D-82538 Geretsried, Germany
[89] - Dittmar F.-W., Weissenbacher E. R. Therapy of adnexitis -
enhancement of the basic antibiotic therapy with hydrolytic enzymes.
International Journal of Experimental and Clinical Chemotherapy
1992: Vol. 5, No. 2, pp. 73-81.
[90] - Shaivok A.V., Movsisyan G.R., Stolyarova A.V. Wogenzym(R) in
teh Treatment of Patients with Juvenile Chronic Arthritis. INt. J.
Immunotherapy XIII(3/4) 93-96 (1997).
[91] - Kovalenko V.,Golovkov Y., Golovatcky I. Using of systemic
enzymotherapy for treatment of rheumatoid arthritis. Rheumatologia
1998, Suppl., Vol. XXXVI, Warsaw 1998, Abst. No. 140, pp. 206.
[92] - Kovalenko V.N., Golovkov Y. Z. Basic treatment of rheumatoid
arthritis: new approaches. Revmatology in Europe 1997, Vol. 26,
Suppl. 2, Abst. 446.
[93] - Naumenko L. Yu. Use of systemic enzyme therapy in the
treatment of hand injuries and their consequences.Presented at the
conference ”Current treatment aspects of wrist injuries and their
consequences”, Dnepropetrovsk 1998
[94] - Kasseroller R., Wenning H.G. Efficacy and tolerability of
proteolytic enzymes as an anti-inflammatory agent in lymphoedema
after axillary dissection due to mammary cancer. The European
Journal of Lymphology, 2002-2003, Vol. 10, No. 37-38, pp. 18-26,
[95] - Szilasiová A., Macejová Ž., Jautová J., Pundová L. Our
experience with Wobenzym in the treatment of patients with
rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78,
No. 7, pp. 366-368.
[96] - Naumenko L. Yu. Use of systemic enzyme therapy in the
treatment of hand injuries and their consequences.Presented at the
conference ”Current treatment aspects of wrist injuries and their
consequences”, Dnepropetrovsk 1998
[97] - LaMarre J, Wollenberg GK, Gonias SL, Hayes MA.
Cytokine binding and clearance properties of
proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991
Jul;65(1):3-14.
[98] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[99] - Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F.
Systemic enzyme therapy in the complex treatment of angina pectoris.
Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120.
[100] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[101] - Samtsov A.V., Mazurov V. I., Tabachnov V.V. Systemic enzyme
therapy in the treatment of neurodermitis (atopic dermatitis)
patients. Skin and Venereal Diseases Department of
Sankt-Petersburg’s Military Medicine Academy Conference "New aspects
of systemic enzyme therapy", Moscow, 1999.
[102] - Vokálová I. Systemic enzyme therapy in the treatment of
children with recurrent infections of respiratory tract. Vox
Pediatriae 2003, Vol. 2., No. 9, pp. 29 – 30.
[103] - Siziakina L.P., Artemenko N.A. Clinical and immunological
criteria of activity of different rheumatic arthritis courses and
their treatment by Wobenzym. III. Internat. Congress on
Immunorehabilitation and Rehabilitation in Medicine, Eilat, Israel,
1997.
[104] - Wrba H. Systemic Enzyme Therapy - Newest Status and
Progress.
Therapie Woche 1987, Jahrgang 37, No. 7
SO 11 (19-02-3).
[105] - Dittmar F.-W., Weissenbacher E. R.
Therapy of adnexitis - enhancement of the basic antibiotic therapy
with hydrolytic enzymes. International Journal of Experimental and
Clinical Chemotherapy 1992: Vol. 5, No. 2, pp. 73-81.
[106] - Lauer D, Reichenbach A, Birkenmeier G. Alpha
2-macroglobulin-mediated degradation of amyloid beta 1--42: a
mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001
Feb;167(2):385-92.
[107] - Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ.
Degradation of amyloid beta-protein by a serine
protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr
5;271(14):8443-51.
[108] - Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA,
Paul SM. alpha2-Macroglobulin as a beta-amyloid peptide-binding
plasma protein. J Neurochem. 1997 Jul;69(1):299-305.
[109] - Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J,
Riedel NG, Sahasrabudhe S. Alpha2-macroglobulin associates with
beta-amyloid peptide and prevents fibril formation. Proc Natl Acad
Sci U S A. 1998 Mar 17;95(6):3275-80.
[110] - Mettenburg JM, Gonias SL. Beta-amyloid peptide binds
equivalently to binary and ternary alpha2-macroglobulin-protease
complexes. Protein J. 2005 Feb;24(2):89-93.
[111] - Qiu Z, Strickland DK, Hyman BT, Rebeck GW.
Alpha2-macroglobulin enhances the clearance of
endogenous soluble beta-amyloid peptide via low-density lipoprotein
receptor-related protein in cortical neurons. J Neurochem. 1999
Oct;73(4):1393-8.
[112] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[113] - Korpan MI, Fialka V. Wobenzyme and diuretic therapy in
lymphedema after breast operation. Wien Med Wochenschr.
1996;146(4):67-72; discussion 74.
[114] - Schlüter, P. Phlogenzym® in the Treatment of Chronic
Prostatitis. PharmaScript, Primelweg 2, D-82538 Geretsried, Germany
Date of report: October 30th, 1997.
[115] - Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral
enzyme combination versus diclofenac in the treatment of
osteoarthritis of the knee--a double-blind prospective randomized
study. Clin Rheumatol. 2004 Oct;23(5):410-5. Epub 2004 Jul 24.
[116] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
© 2009, Joseph J
Collins, RN, ND